angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
On 15 October 1940, doses of penicillin were administered to two patients with bacterial endocarditis at the Presbyterian Hospital in New York City, Aaron Alston and Charles Aronson. They became the first persons to receive penicillin treatment in the United States. The Columbia team presented the results of their penicillin treatment of the four patients at the annual meeting of the American Society for Clinical Investigation in Atlantic City, New Jersey, on 5 May 1941. Their paper was reported on by William L. Laurence in The New York Times and generated great public interest.
=== Primary and secondary schools === Cold Spring is served by ROCORI Independent School District 750. ROCORI stands for the three adjacent communities that primarily comprise the schools: Rockville, Cold Spring, and Richmond. Local public schools serving Cold Spring include John Clark Elementary, Cold Spring Elementary and Richmond Elementary, ROCORI Middle School, and Rocori High School. There are also three private schools in the district: St. Peter & Paul Elementary (preK-5) in Richmond, St. Boniface Elementary (preK-6) in Cold Spring, and Holy Cross School (preK-6) in Pearl Lake.
2 I− + 2 Fe3+ → I2 + 2 Fe2+ (E0 = +0.23 V) Ferric iodide, a black solid, is not stable in ordinary conditions, but can be prepared through the reaction of iron pentacarbonyl with iodine and carbon monoxide in the presence of hexane and light at the temperature of −20 °C, with oxygen and water excluded. Complexes of ferric iodide with some soft bases are known to be stable compounds.
== Clinical significance == Toxic vacuolation is associated with sepsis, particularly when accompanied by toxic granulation. The finding is also associated with bacterial infection, alcohol toxicity, liver failure, and treatment with granulocyte colony-stimulating factor, a cytokine drug used to increase the absolute neutrophil count in patients with neutropenia. The formation of toxic vacuoles represents increased phagocytic activity, which is stimulated by the release of cytokines in response to inflammation or tissue injury. Toxic vacuolation frequently occurs in conjunction with toxic granulation and Döhle bodies in inflammatory states, and these findings are collectively referred to as toxic changes. Neutrophilia and left shift (the presence of immature neutrophil precursors such as band neutrophils and metamyelocytes in the peripheral blood) often accompany toxic changes, as these phenomena also occur in response to inflammation. It has been suggested that neutrophil vacuoles not be labelled "toxic vacuoles" unless they are accompanied by other toxic changes, as vacuolation can occur in other conditions.
Sources: en.wikipedia.org
Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987). "An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes". J. Biol. Chem. 262 (18): 8532–6. doi:10.1016/S0021-9258(18)47446-7. PMID 3597387. Fischer WH, Spiess J (1987). "Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3628–32. Bibcode:1987PNAS...84.3628F. doi:10.1073/pnas.84.11.3628. PMC 304928. PMID 3473473. Messer M; Ottesen M (1965). "Isolation and properties of glutamine cyclotransferase of dried papaya latex". C. R. Trav. Lab. Carlsberg. 35 (1): 1–24. PMID 5846578.
Pediatric (also paediatric or pædiatric) dentists promote the dental health of children as well as serve as educational resources for parents. It is recommended by the American Academy of Pediatric Dentistry (AAPD) and the American Academy of Pediatrics (AAP) that a dental visit occurs after the presence of the first tooth or by a child's first birthday. The AAPD has said that it is important to establish a comprehensive and accessible ongoing relationship between the dentist and patient – referring to this as the patient's "dental home". This is because early oral examination aids in the detection of the early stages of tooth decay. Early detection is essential to maintain oral health, modify aberrant habits, and treat as needed and as simply as possible. Additionally, parents are given a program of preventive home care (brushing, flossing and fluorides), a caries risk assessment, information on finger, thumb, and pacifier habits, and may include advice on preventing injuries to the mouth and teeth of children, diet counseling, and information on growth and development.
=== Pharmacodynamics === Cyclofenil is a SERM, or a mixed agonist and antagonist of the estrogen receptors (ERs). It is described as a relatively weak/mild SERM. The medication is generally less effective than other SERMs. The medication is an "impeded estrogen" and is thought to work as a progonadotropin by blocking the actions of estrogens in the pituitary gland and hypothalamus, thereby disinhibiting release of the gonadotropins luteinizing hormone and follicle-stimulating hormone. In men, cyclofenil can increase testosterone levels due its progonadotropic effects.
== Sources cited == Emsley, John (2001). "Uranium". Nature's Building Blocks: An A to Z Guide to the Elements. Oxford, England: Oxford University Press. pp. 476–482. ISBN 978-0-19-850340-8. Seaborg, Glenn T. (1968). "Uranium". The Encyclopedia of the Chemical Elements. Skokie, Illinois: Reinhold Book Corporation. pp. 773–786. LCCN 68029938. Groves, Leslie R. (1962). Now It Can Be Told: The Story of the Manhattan Project. New York: Harper and Company. ISBN 0-306-80189-2. {{cite book}}: ISBN / Date incompatibility (help)
The majority of I-131 will be eliminated from the human body in 3–5 days, through natural decay, and through excretion in sweat and urine. Smaller amounts will continue to be released over the next several weeks, as the body processes thyroid hormones created with the I-131. For this reason, it is advised to regularly clean toilets, sinks, bed sheets and clothing used by the person who received the treatment. Patients may also be advised to wear slippers or socks at all times, and avoid prolonged close contact with others. This minimizes accidental exposure by family members, especially children. Use of a decontaminant specially made for radioactive iodine removal may be advised. The use of chlorine bleach solutions, or cleaners that contain chlorine bleach for cleanup, are not advised, since radioactive elemental iodine gas may be released. Airborne I-131 may cause a greater risk of second-hand exposure, spreading contamination over a wide area. Patient is advised if possible to stay in a room with a bathroom connected to it to limit unintended exposure to family members. Many airports have radiation detectors to detect the smuggling of radioactive materials. Patients should be warned that if they travel by air, they may trigger radiation detectors at airports up to 95 days after their treatment with 131I.
Sources: en.wikipedia.org
Generative engine optimization (GEO) is the practice of structuring digital content and managing online presence to improve visibility in responses generated by generative AI systems. The practice influences the way large language models (LLMs) retrieve, summarize, and present information in response to user queries. Related terms include answer engine optimization (AEO) and artificial intelligence optimization (AIO).
The mucosa is the innermost layer of the gastrointestinal tract. The mucosa surrounds the lumen, or open space within the tube. This layer comes in direct contact with digested food (chyme). The mucosa is made up of:
Since the details regarding such variables as test species, receptor source, route of administration, drug concentration, and stereochemical composition are important but often incomplete in other Reviews and Abstracts of research publications, many are provided in the more technical review below, in order to support as fully as possible the broad statements made in this Synopsis.
== Application in human evolution and disease == In the human genome, the frequency and characteristics of de novo mutations have been studied as important contextual factors to our evolution. Compared to the human reference genome, a typical human genome varies at approximately 4.1 to 5.0 million loci, and the majority of this genetic diversity is shared by nearly 0.5% of the population. The typical human genome also contains 40,000 to 200,000 rare variants observed in less than 0.5% of the population that can only have occurred from at least one de novo germline mutation in the history of human evolution. De novo mutations have also been researched as playing a crucial role in the persistence of genetic disease in humans. With recents advancements in next-generation sequencing (NGS), all types of de novo mutations within the genome can be directly studied, the detection of which provides a magnitude of insight toward the causes of both rare and common genetic disorders. Currently, the best estimate of the average human germline SNV mutation rate is 1.18 x 10^-8, with an approximate ~78 novel mutations per generation. The ability to conduct whole genome sequencing of parents and offspring allows for the comparison of mutation rates between generations, narrowing down the origin possibilities of certain genetic disorders.
{\displaystyle u(r,t)={\frac {G}{4\mu }}\left(R^{2}-r^{2}\right)-{\frac {2GR^{2}}{\mu }}\sum _{n=1}^{\infty }{\frac {1}{\lambda _{n}^{3}}}{\frac {J_{0}(\lambda _{n}r/R)}{J_{1}(\lambda _{n})}}e^{-\lambda _{n}^{2}\nu t/R^{2}},\quad J_{0}\left(\lambda _{n}\right)=0}
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.